# Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.

> **NCT05489406** · PHASE1 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 16 (actual)

## Conditions studied

- Hiv

## Interventions

- **DRUG:** DTG DT (6 x 5 mg)
- **DRUG:** F/TAF TOS (3 x 60/7.5 mg)

## Key facts

- **NCT ID:** NCT05489406
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-06
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-11-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489406, "Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05489406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*